Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study
Open-label Extension Study to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of AT1001 in Patients With Fabry Disease
Sponsor: Amicus Therapeutics
Terminated
The Sponsor (Amicus Therapeutics) terminated this study for logistical reasons.
Other terminated trials from Amicus Therapeutics
Other Fabry Disease trials with similar outcome
This PHASE2 trial investigates Fabry Disease and is currently terminated or withdrawn. Amicus Therapeutics leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amicus Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .